| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
4.02
|
|
2
|
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
|
BMJ
|
2012
|
3.82
|
|
3
|
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
2.63
|
|
4
|
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
|
J Clin Oncol
|
2011
|
2.58
|
|
5
|
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
|
Cancer Prev Res (Phila)
|
2008
|
2.23
|
|
6
|
A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
2.15
|
|
7
|
Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
2.14
|
|
8
|
Metformin reduces endogenous reactive oxygen species and associated DNA damage.
|
Cancer Prev Res (Phila)
|
2012
|
2.10
|
|
9
|
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
2.01
|
|
10
|
Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.95
|
|
11
|
Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.91
|
|
12
|
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
|
Gynecol Oncol
|
2008
|
1.88
|
|
13
|
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor.
|
Clin Cancer Res
|
2007
|
1.84
|
|
14
|
Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer.
|
J Natl Cancer Inst
|
2013
|
1.80
|
|
15
|
Association of markers of insulin and glucose control with subsequent colorectal cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
1.75
|
|
16
|
A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts.
|
J Natl Cancer Inst
|
2012
|
1.74
|
|
17
|
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
|
Breast Cancer Res Treat
|
2010
|
1.67
|
|
18
|
Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.
|
J Clin Oncol
|
2011
|
1.64
|
|
19
|
Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada.
|
Int J Cancer
|
2006
|
1.58
|
|
20
|
Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.50
|
|
21
|
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.
|
Cancer Res
|
2013
|
1.49
|
|
22
|
Racial differences in premenopausal endogenous hormones.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.45
|
|
23
|
Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.44
|
|
24
|
Body shape throughout life and correlations with IGFs and GH.
|
Endocr Relat Cancer
|
2007
|
1.43
|
|
25
|
The use of metformin and the incidence of lung cancer in patients with type 2 diabetes.
|
Diabetes Care
|
2012
|
1.42
|
|
26
|
Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
|
Endocr Relat Cancer
|
2006
|
1.40
|
|
27
|
Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
|
Cancer Causes Control
|
2005
|
1.33
|
|
28
|
Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.31
|
|
29
|
Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
|
Carcinogenesis
|
2007
|
1.29
|
|
30
|
Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.28
|
|
31
|
C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.27
|
|
32
|
Hormonal profile of diabetic men and the potential link to prostate cancer.
|
Cancer Causes Control
|
2008
|
1.26
|
|
33
|
Soy isoflavones in the treatment of prostate cancer.
|
Nutr Cancer
|
2003
|
1.24
|
|
34
|
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
|
Cancer Res
|
2007
|
1.22
|
|
35
|
Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer.
|
Cancer Res
|
2007
|
1.21
|
|
36
|
Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study.
|
Breast Cancer Res
|
2007
|
1.20
|
|
37
|
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease.
|
Int J Cancer
|
2010
|
1.18
|
|
38
|
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.
|
Hum Mol Genet
|
2010
|
1.18
|
|
39
|
Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke.
|
J Clin Endocrinol Metab
|
2007
|
1.16
|
|
40
|
A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer.
|
Int J Cancer
|
2002
|
1.15
|
|
41
|
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
|
J Thorac Oncol
|
2009
|
1.14
|
|
42
|
Milk consumption and the prepubertal somatotropic axis.
|
Nutr J
|
2007
|
1.14
|
|
43
|
Metabolic syndrome components and colorectal adenoma in the CLUE II cohort.
|
Cancer Causes Control
|
2009
|
1.13
|
|
44
|
Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation.
|
Aging Cell
|
2013
|
1.13
|
|
45
|
Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk.
|
Int J Cancer
|
2003
|
1.10
|
|
46
|
A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3.
|
Hum Mol Genet
|
2011
|
1.10
|
|
47
|
Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
|
Cancer Res
|
2010
|
1.08
|
|
48
|
Carbon source and myc expression influence the antiproliferative actions of metformin.
|
Cancer Res
|
2012
|
1.07
|
|
49
|
Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.07
|
|
50
|
Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
|
Gynecol Oncol
|
2005
|
1.06
|
|
51
|
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
1.04
|
|
52
|
Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.02
|
|
53
|
Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.02
|
|
54
|
Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3.
|
Am J Epidemiol
|
2011
|
1.00
|
|
55
|
Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects.
|
Mech Ageing Dev
|
2009
|
0.99
|
|
56
|
Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study.
|
J Clin Endocrinol Metab
|
2012
|
0.99
|
|
57
|
Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults.
|
J Am Geriatr Soc
|
2008
|
0.98
|
|
58
|
High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly.
|
Am Heart J
|
2008
|
0.97
|
|
59
|
Effects of lycopene supplementation in patients with localized prostate cancer.
|
Exp Biol Med (Maywood)
|
2002
|
0.97
|
|
60
|
Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort.
|
Prostate
|
2010
|
0.97
|
|
61
|
A prospective study of circulating adipokine levels and risk of multiple myeloma.
|
Blood
|
2012
|
0.97
|
|
62
|
Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men.
|
Am J Epidemiol
|
2003
|
0.97
|
|
63
|
Fasting insulin levels and cognitive decline in older women without diabetes.
|
Neuroepidemiology
|
2008
|
0.96
|
|
64
|
Plasma IGF-I levels and cognitive performance in older women.
|
Neurobiol Aging
|
2005
|
0.95
|
|
65
|
Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004.
|
Int J Cancer
|
2011
|
0.95
|
|
66
|
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
|
Breast Cancer Res Treat
|
2014
|
0.95
|
|
67
|
Glioma risk in relation to serum levels of insulin-like growth factors.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.95
|
|
68
|
Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.92
|
|
69
|
Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin.
|
PLoS One
|
2012
|
0.92
|
|
70
|
Insulin-like growth factors and leukocyte telomere length: the cardiovascular health study.
|
J Gerontol A Biol Sci Med Sci
|
2009
|
0.91
|
|
71
|
Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.90
|
|
72
|
Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study.
|
Cancer Causes Control
|
2014
|
0.89
|
|
73
|
Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3).
|
Growth Horm IGF Res
|
2006
|
0.89
|
|
74
|
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies.
|
Breast Cancer Res Treat
|
2012
|
0.89
|
|
75
|
Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II.
|
Breast Cancer Res
|
2012
|
0.88
|
|
76
|
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
|
Clin Cancer Res
|
2014
|
0.88
|
|
77
|
The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.88
|
|
78
|
Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
|
Horm Cancer
|
2010
|
0.87
|
|
79
|
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
|
Breast Cancer Res
|
2014
|
0.87
|
|
80
|
Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.
|
Int J Cancer
|
2014
|
0.87
|
|
81
|
No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
0.86
|
|
82
|
Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.86
|
|
83
|
Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.
|
Mol Cancer Ther
|
2013
|
0.86
|
|
84
|
Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.86
|
|
85
|
Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer.
|
PLoS One
|
2011
|
0.86
|
|
86
|
Type 2 diabetes and the risk of mortality among patients with prostate cancer.
|
Cancer Causes Control
|
2014
|
0.85
|
|
87
|
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
|
Gynecol Oncol
|
2009
|
0.85
|
|
88
|
A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation.
|
Int J Geriatr Psychiatry
|
2009
|
0.83
|
|
89
|
Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.82
|
|
90
|
Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes.
|
Psychoneuroendocrinology
|
2008
|
0.82
|
|
91
|
Racial variation in vitamin D cord blood concentration in white and black male neonates.
|
Cancer Causes Control
|
2012
|
0.82
|
|
92
|
Fasting plasma insulin, C-peptide and cognitive change in older men without diabetes: results from the Physicians' Health Study II.
|
Neuroepidemiology
|
2010
|
0.82
|
|
93
|
Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates.
|
Cancer Causes Control
|
2012
|
0.81
|
|
94
|
Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
0.81
|
|
95
|
Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada).
|
Cancer Causes Control
|
2014
|
0.81
|
|
96
|
Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.79
|
|
97
|
Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
|
J Natl Cancer Inst
|
2003
|
0.75
|
|
98
|
A prospective study of insulin-like growth factor 1, its binding protein 3, and risk of endometriosis.
|
Am J Epidemiol
|
2015
|
0.75
|
|
99
|
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
|
100
|
Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer.
|
Cancer Causes Control
|
2013
|
0.75
|